It is a rare scenario where long-term interest rates suddenly fall below short-term interest rates.Real Estateread more
It was the third trigger of the recession indicator in less than two weeks.Bondsread more
Overstock CEO Partick Byrne has resigned from the e-commerce company after making comments about his role in the "deep state."Technologyread more
Last quarter as Facebook struggled with data leaks and fake news scandals, insiders at the company were selling more stock than they typically do.Investingread more
Automakers are trying to deal with President Trump's efforts to roll back Obama-era fuel efficiency rules.Autosread more
Palantir CEO Alex Karp said billionaire investor Peter Thiel is right to question Google's decision to work in China, while abandoning military contracts in the US.Technologyread more
These are the stocks posting the largest moves midday.Market Insiderread more
U.S. manufacturer growth slowed to the lowest level in almost 10 years in August, the latest sign that the trade war may be exacerbating the economic slowdown.Marketsread more
L Brands shares fell by as much as 12% at one point, touching $17.61 — a price not seen since December 2009.Retailread more
"The president is not backing down," says CNBC's Jim Cramer, referring to Trump's repeated calls for the Fed to cut rates while talking tough on China.Economyread more
The market rebound this week hasn't convinced the strategist predicting a "Lehman-like" sell-off that the risk is completely off the table.Marketsread more
(Adds details on quarter)
April 30 (Reuters) - U.S. drugmaker Eli Lilly and Co cut its full-year revenue forecast on Tuesday, as it predicted further hits from price declines in the United States and increased generic competition for drugs including erectile dysfunction treatment Cialis.
Shares of the company were down 3 percent at $115.99 before the bell.
The drugmaker now expects 2019 revenue between $22.0 billion and $22.5 billion, lower than its prior forecast of $25.1 billion to $25.6 billion. Analysts had expected $22.17 billion.
Lilly said it also expects to be impacted by the global withdrawal of its cancer drug Lartruvo, a major setback to its cancer treatment portfolio as its older drugs face intensifying competition.
The company, however, raised its adjusted earnings forecast to $5.60 to $5.70 per share from a prior range of $5.55 to $5.65, ahead of the average analyst estimate of $5.63.
Excluding items, the company earned $1.33 per share, beating estimates of $1.31, according to IBES data from Refinitiv.
Best-selling diabetes drug Trulicity brought in $879.7 million, missing the average analyst estimate of $952 million.
Net income more than tripled to $4.24 billion, or $4.31 per share, in the quarter ended March 31, as the company benefited from a $3.7 billion gain from its spin-off of animal health unit Elanco.
Revenue rose to $5.09 billion, but missed estimates of $5.13 billion due to lower realized prices. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)